Bill Gimson, executive director of the embattled Cancer Prevention and Research Institute of Texas, has submitted his resignation, which will take effect Jan. 17. The agency had been embroiled in controversy over its granting of $11 million to a Dallas company without sufficient scientific review, and is now facing an investigation by the attorney general’s office. Officials will try to determine whether any of the agency’s staff members benefited financially from the award to Peloton Therapeutics.